Literature DB >> 34762262

Expression and associated epigenetic mechanisms of the Ca2+-signaling genes in breast cancer subtypes and epithelial-to-mesenchymal transition.

Andrés Hernández-Oliveras1, Ángel Zarain-Herzberg2.   

Abstract

Breast cancer-associated deaths are related mainly to specific molecular subtypes and the presence of metastasis. The Epithelial-to-Mesenchymal Transition (EMT) and Ca2+ signaling pathways are involved in breast cancer metastasis, and they are regulated in part by epigenetic mechanisms. Moreover, activation of EMT modulates Ca2+ concentration and in turn, Ca2+ signaling regulates the expression of EMT markers. Also, activation of Ca2+ signaling genes with epigenetic inhibitors reverts the EMT. Thus, Ca2+ signaling might have an important role in breast cancer metastasis and EMT, particularly through the epigenetic regulation of genes involved in its signaling. However, little is known due to that an estimate of 1670 genes participate in the Ca2+ signaling and only a few genes have been studied. Here, we aimed to explore the expression of all genes involved in Ca2+ signaling in all breast cancer subtypes and EMT, and whether modulation of epigenetic mechanisms is related to their expression. Several genes of the Ca2+ signaling are altered in all breast cancer subtypes, being the cadherins and voltage channels the most frequent altered genes. Also, DNA methylation and histone posttranslational modifications showed a good correlation with their altered expression. The expression of the cadherins and voltage channels is also modulated during breast EMT, and ATAC-seq results suggest that chromatin rearrangement at their promoter is involved. In conclusion, the expression of the genes involved in Ca2+ signaling is altered in all breast cancer subtypes and during EMT, and epigenetic mechanisms are an attractive target to regulate their expression.
© 2021. The International CCN Society.

Entities:  

Keywords:  Breast cancer; Calcium signaling; Epigenetics; Epithelial-to-mesenchymal transition; Gene expression

Year:  2021        PMID: 34762262      PMCID: PMC9411462          DOI: 10.1007/s12079-021-00655-x

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.908


  70 in total

1.  Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.

Authors:  Erika da Costa Prando; Luciane Regina Cavalli; Cláudia Aparecida Rainho
Journal:  Epigenetics       Date:  2011-12       Impact factor: 4.528

2.  Identification of Fat4 as a candidate tumor suppressor gene in breast cancers.

Authors:  Chao Qi; Yiwei Tony Zhu; Liping Hu; Yi-Jun Zhu
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

3.  Transcriptional and epigenetic landscape of Ca2+-signaling genes in hepatocellular carcinoma.

Authors:  Andrés Hernández-Oliveras; Eduardo Izquierdo-Torres; Guadalupe Hernández-Martínez; Ángel Zarain-Herzberg; Juan Santiago-García
Journal:  J Cell Commun Signal       Date:  2021-01-04       Impact factor: 5.782

4.  Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells.

Authors:  Malika Faouzi; Frederic Hague; Marie Potier; Ahmed Ahidouch; Henri Sevestre; Halima Ouadid-Ahidouch
Journal:  J Cell Physiol       Date:  2011-02       Impact factor: 6.384

5.  Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development.

Authors:  H Carlsson; S Petersson; C Enerbäck
Journal:  Int J Oncol       Date:  2005-12       Impact factor: 5.650

Review 6.  Molecular mechanisms of tumour invasion: regulation by calcium signals.

Authors:  Oksana Iamshanova; Alessandra Fiorio Pla; Natalia Prevarskaya
Journal:  J Physiol       Date:  2017-04-21       Impact factor: 5.182

7.  Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.

Authors:  Po-Hao Chang; Min-Che Chen; Ya-Ping Tsai; Grace Y T Tan; Pang-Hung Hsu; Yung-Ming Jeng; Yi-Fang Tsai; Muh-Hwa Yang; Wendy W Hwang-Verslues
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

8.  Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.

Authors:  Hector L Franco; Anusha Nagari; Venkat S Malladi; Wenqian Li; Yuanxin Xi; Dana Richardson; Kendra L Allton; Kaori Tanaka; Jing Li; Shino Murakami; Khandan Keyomarsi; Mark T Bedford; Xiaobing Shi; Wei Li; Michelle C Barton; Sharon Y R Dent; W Lee Kraus
Journal:  Genome Res       Date:  2017-12-22       Impact factor: 9.043

9.  Clustered protocadherins methylation alterations in cancer.

Authors:  Ana Florencia Vega-Benedetti; Eleonora Loi; Loredana Moi; Sylvain Blois; Antonio Fadda; Manila Antonelli; Antonella Arcella; Manuela Badiali; Felice Giangaspero; Isabella Morra; Amedeo Columbano; Angelo Restivo; Luigi Zorcolo; Viviana Gismondi; Liliana Varesco; Sara Erika Bellomo; Silvia Giordano; Matteo Canale; Andrea Casadei-Gardini; Luca Faloppi; Marco Puzzoni; Mario Scartozzi; Pina Ziranu; Giuseppina Cabras; Pierluigi Cocco; Maria Grazia Ennas; Giannina Satta; Mariagrazia Zucca; Daniele Canzio; Patrizia Zavattari
Journal:  Clin Epigenetics       Date:  2019-07-09       Impact factor: 6.551

10.  Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling.

Authors:  Dengfei Xu; Hui Yuan; Zihong Meng; Chunmei Yang; Zefang Li; Mengge Li; Zhigang Zhang; Yu Gan; Hong Tu
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.